Sage adds titles in Therapeutic series
The drug safety title will cover the safety issues pertaining to the use of drugs in different age and ethnic patient groups, adverse drug reactions, drug interactions, pharmacovigilance, risk management and other topics. The hematology title will focus on the research and practice of hematology, and will publish original research and reviews across all areas of hematology, including malignant myeloid and lymphoid disorders, red cell and platelet disorders, and other relevant topics, according to a statement on the launch.
“Rapid publication of high-quality articles from respected researchers and key opinion leaders” has been key to the success of the Therapeutic Advances series, said Gordon Mallarkey, managing editor of Therapeutic Advances in Drug Safety, in an email. “We publish articles of clinical relevance to physicians, to help them with patient management and prescribing decisions.”
Roberto Mastrorilli, Sage's head of commercial sales, said the titles are open to pharmaceutical product advertisers “wishing to target these niche audiences as part of their marketing plans.”
The two new journals, joining nine pre-existing titles in the series, are available free of charge for the first three years, to build readership.